Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); August 10 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with...
2023-06-30 06:07:11 ET Stock index futures rose early Friday following strong U.S. economic data , which grew much more than initially thought in the first quarter. The focus is now on the U.S. personal consumption expenditures price index, or the Fed's favorite inflation ...
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo Elafibranor was well tolerated with a safety profile consistent with previous studies Results position elafi...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); June 7 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...
E xclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver disease Preclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in ...
2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...
Q uorum of 29.54 % on first convening ; allowing approval of all the resolutions recommended by the Board of Directors Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 24 , 2023 - GENFIT (...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); May 23 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...
Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmace...
2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...
News, Short Squeeze, Breakout and More Instantly...
Genfit Ord Company Name:
GNFTF Stock Symbol:
OTCMKTS Market:
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...